Rationale and design of RE - LY : randomized evaluation of <font color="blue">long_1</font> <font color="blue">-_1</font> <font color="blue">term_1</font> <font color="blue">anticoagulant_1</font> <font color="blue">therapy_1</font> <font color="blue">,_1</font> warfarin , compared with dabigatran . 
<br>
<br> Vitamin K antagonists ( VKAs ) are effective for stroke prevention in <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">atrial_3</font> <font color="blue">fibrillation_3</font> <font color="blue">(_3</font> <font color="blue">AF_3</font> <font color="blue">)_3</font> but are difficult to use . Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran . It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin ( international normalized ratio 2 - 3 ) in the RE - LY trial . Two doses of dabigatran ( 110 and 150 mg BID ) are being evaluated . <font color="blue">RE_1</font> <font color="blue">-_1</font> <font color="blue">LY_1</font> <font color="blue">is_1</font> <font color="blue">a_1</font> <font color="blue">phase_1</font> <font color="blue">3_1</font> <font color="blue">,_1</font> <font color="blue">prospective_1</font> <font color="blue">,_1</font> <font color="blue">randomized_1</font> <font color="blue">,_1</font> <font color="blue">open_1</font> <font color="blue">-_1</font> <font color="blue">label_1</font> <font color="blue">multinational_2</font> <font color="blue">(_2</font> <font color="blue">44_2</font> <font color="blue">countries_2</font> <font color="blue">)_2</font> <font color="blue">trial_2</font> <font color="blue">of_2</font> <font color="blue">patients_2</font> <font color="blue">with_2</font> <font color="blue">nonvalvular_2</font> <font color="blue">AF_2</font> <font color="blue">and_2</font> <font color="blue">at_2</font> <font color="blue">least_2</font> <font color="blue">1_2</font> <font color="blue">risk_2</font> <font color="blue">factor_2</font> <font color="blue">for_2</font> <font color="blue">stroke_2</font> <font color="blue">._2</font> <font color="blue">Recruitment_1</font> <font color="blue">concluded_1</font> <font color="blue">with_1</font> <font color="blue">a_1</font> <font color="blue">total_1</font> <font color="blue">of_1</font> <font color="blue">18,113_3</font> <font color="blue">patients_3</font> <font color="blue">._3</font> <font color="blue">Patients_4</font> <font color="blue">who_4</font> <font color="blue">were_4</font> <font color="blue">VKA_5</font> <font color="blue">-_5</font> <font color="blue">naive_5</font> <font color="blue">and_5</font> <font color="blue">experienced_5</font> <font color="blue">are_2</font> <font color="blue">included_2</font> <font color="blue">in_2</font> <font color="blue">balanced_2</font> <font color="blue">proportions_2</font> <font color="blue">._2</font> The primary outcome is <font color="blue">stroke_1</font> ( including hemorrhagic ) or <font color="blue">systemic_1</font> <font color="blue">embolism_1</font> <font color="blue">._1</font> Safety outcomes are bleeding , liver function abnormalities , and other adverse events . Adjudication of end points is blinded to drug assignment . The trial is expected to accrue a minimum of <font color="blue">450_1</font> events with a minimum 1-year of follow - up . RE - LY is the largest AF stroke prevention trial yet undertaken . It is unique because it includes equal numbers of VKA - experienced and naive patients and evaluates 2 different dosages of dabigatran , which may allow tailoring of dosing to individual patient needs . The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial . Results are expected in 2009 .